Sleep Number Corporation shares fall 4.16% intraday due to DNB Carnegie lowering target value and citing subscriber growth challenges.

Sleep Number Corporation declined 4.16% intraday, with the company facing short-term challenges due to weakening subscriber growth. DNB Carnegie, an investment bank, acknowledged continued strong cash flows and progress in Sleep Cycle's sleep apnea project but revised its sales forecasts downward for 2025-27 and adjusted its valuation range to SEK 31-41, down from the previous SEK 35-46. The bank believes that subscriber trends will dictate the share price in the short term.